Invirase Side Effects

Generic name: saquinavir

Medically reviewed by Drugs.com. Last updated on Nov 22, 2023.

Note: This document provides detailed information about Invirase Side Effects associated with saquinavir. Some dosage forms listed on this page may not apply specifically to the brand name Invirase.

Applies to saquinavir: oral tablet.

Serious side effects of Invirase

Along with its needed effects, saquinavir (the active ingredient contained in Invirase) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking saquinavir:

More common side effects

• chest pain
• chills
• cough
• fever
• increased amount of fat in the upper back and neck, or around the chest and stomach area
• loss of fat from the legs, arms, and face
• sneezing
• sore throat
• tightness in the chest
• trouble breathing

Less common side effects

• blurred vision
• cough-producing mucus
• diarrhea
• dry mouth
• flushed, dry skin
• fruit-like breath odor
• general feeling of discomfort or illness
• headache
• increased hunger
• increased thirst
• increased urination
• joint pain
• loss of appetite
• loss of consciousness
• muscle aches and pains
• nausea
• runny nose
• shivering
• skin rash
• sore throat
• stomachache
• sweating
• trouble sleeping
• unexplained weight loss
• unusual tiredness or weakness
• vomiting

Rare side effects

• burning or prickling sensation
• confusion
• dehydration
• dry or itchy skin

Other side effects of Invirase

Some side effects of saquinavir may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common side effects

• back pain
• belching
• bloated or full feeling
• change in taste
• decreased interest in sexual intercourse
• difficulty having a bowel movement
• discouragement
• excess air or gas in the stomach or bowels
• fear
• feeling sad or empty
• headache
• heartburn
• inability to have or keep an erection
• indigestion
• irritability
• lack of appetite
• loss in sexual ability, desire, drive, or performance
• loss of interest or pleasure
• mouth ulcers
• nervousness
• pain or tenderness around the eyes and cheekbones
• passing gas
• skin rash, encrusted, scaly, and oozing
• skin warts
• stomach upset, discomfort, or pain
• stuffy nose
• tiredness
• trouble concentrating
• weakness

For healthcare professionals

Applies to saquinavir: oral capsule, oral tablet.

General adverse events

Nausea, vomiting, diarrhea, fatigue, flatulence, and abdominal pain have been reported the most frequently with this drug (plus ritonavir). Additional side effects have been reported during postmarketing experience that were similar to those observed in clinical trials with saquinavir (the active ingredient contained in Invirase) mesylate and saquinavir soft gel capsules alone or in combination with ritonavir.^[Ref]

Gastrointestinal

• Very common (10% or more): Nausea, diarrhea
• Common (1% to 10%): Vomiting, abdominal distension, abdominal pain, upper abdominal pain, constipation, dry mouth, dyspepsia, eructation, flatulence, lip dry, loose stools, increased blood amylase
• Uncommon (0.1% to 1%): Pancreatitis
• Frequency not reported: Abdominal discomfort, ascites, bucca mucosa ulceration, dysphagia, gastritis, gastrointestinal (GI) hemorrhage, intestinal obstruction, cheilitis, frequent bowel movements, discolored feces, bloodstained feces, gastralgia, GI inflammation, gingivitis, GI ulcer, glossitis, hemorrhoids, melena, painful defecation, parotid disorder, rectal hemorrhage, salivary gland disorder, stomatitis, tooth disorder, abdominal colic, esophageal ulceration, esophagitis, gastroesophageal reflux, infectious diarrhea, pruritus ani, pyrosis, stomach upset, toothache^[Ref]

Metabolic

• Very common (10% or more): Increased blood cholesterol, increased blood triglycerides, increased low-density lipoprotein
• Common (1% to 10%): Diabetes mellitus/hyperglycemia, anorexia, increased appetite
• Uncommon (0.1% to 1%): Decreased appetite
• Frequency not reported: Dehydration, hypertriglyceridemia, increased alkaline phosphatase, increased LDH, hypoglycemia, hyperlipidemia, appetite disturbance, increased blood glucose, decreased blood glucose, hypercalcemia, hypocalcemia, hyperphosphatemia, hypophosphatemia, hyperkalemia, hypokalemia, hypernatremia, hyponatremia
• Postmarketing reports: Ketoacidosis, metabolic abnormalities (e.g., hypertriglyceridemia, hypercholesterolemia, insulin resistance, hyperlactatemia)

Antiretroviral therapy:

• Frequency not reported: Redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance"), increased blood lipid levels, increased glucose levels

Protease inhibitor therapy:

• Postmarketing reports: New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, hyperglycemia, diabetic ketoacidosis^[Ref]

Diabetes mellitus/hyperglycemia was sometimes associated with ketoacidosis during postmarketing experience.

Redistribution/accumulation of body fat has been reported with antiretroviral therapy; causality has not been established.^[Ref]

Hematologic

• Very common (10% or more): Decreased platelet count
• Common (1% to 10%): Anemia, decreased hemoglobin, decreased lymphocyte count, decreased WBC count
• Uncommon (0.1% to 1%): Neutropenia
• Frequency not reported: Hemolytic anemia, leukopenia, lymphadenopathy, pancytopenia, thrombocytopenia, splenomegaly, dermal bleeding, microhemorrhages

Protease inhibitor therapy:

• Frequency not reported: Increased bleeding (including spontaneous skin hematomas, hemarthrosis) in hemophiliacs^[Ref]

Increased bleeding (including spontaneous skin hematomas and hemarthrosis) in patients with hemophilia type A and B has been associated with protease inhibitors. In many of the reported cases, treatment with protease inhibitors was continued or restarted and some patients required additional factor VIII. A causal relationship between protease inhibitor therapy and these episodes has not been established.^[Ref]

Hepatic

• Very common (10% or more): Elevated ALT, elevated AST
• Common (1% to 10%): Increased blood bilirubin
• Uncommon (0.1% to 1%): Hepatitis, jaundice
• Frequency not reported: Chronic active hepatitis, hepatomegaly, hyperbilirubinemia, portal hypertension, elevated GGT, hepatosplenomegaly, severe cutaneous reaction associated with increased liver function tests, increased transaminase levels, exacerbation of chronic liver disease with grade 4 elevated liver function tests, worsening liver disease, severe hepatocellular toxicity (presenting as increased hepatic transaminases), sclerosing cholangitis, cholelithiasis, liver enzyme disorder^[Ref]

There have been reports of worsening liver disease in patients with underlying hepatitis B or C, cirrhosis, chronic alcoholism, and/or other underlying liver abnormalities.

Severe hepatocellular toxicity (which presented as increased hepatic transaminases) occurred in healthy subjects exposed to this drug (plus ritonavir) and rifampin. Transaminases increased up to more than 20-fold the upper limit of normal in some patients and were associated with GI symptoms (including abdominal pain, gastritis, nausea, vomiting). Clinical symptoms resolved and hepatic transaminases returned to normal after all 3 drugs were stopped.^[Ref]

Cardiovascular

• Rare (less than 0.1%): Second or third degree atrioventricular block
• Frequency not reported: QT interval prolongation, PR interval prolongation, heart murmur, hypertension, hypotension, thrombophlebitis, vasoconstriction/peripheral vasoconstriction, cyanosis, heart rate disorder, heart valve disorder, vein distension
• Postmarketing reports: Torsades de pointes (rarely)^[Ref]

This drug (plus ritonavir) showed a dose-dependent prolongation of the QT and PR intervals.^[Ref]

Other

• Common (1% to 10%): Fatigue, fever/pyrexia, asthenia/weakness, increased fat tissue, malaise
• Uncommon (0.1% to 1%): Mucosal ulceration
• Frequency not reported: Chest pain, edema, wasting syndrome, intoxication, increased weight, mucosal damage, retrosternal pain, shivering, generalized weakness, earache, ear pressure, otitis, abscess, bacterial infection, candidiasis, herpes simplex, herpes zoster, mycotic infection, staphylococcal infections, decreased weight, external parasites, cellulitis, molluscum contagiosum, moniliasis

Antiretroviral therapy:

• Frequency not reported: Increased weight^[Ref]

Respiratory

• Common (1% to 10%): Pneumonia, bronchitis, influenza, sinusitis, dyspnea
• Frequency not reported: Cough, epistaxis, hemoptysis, laryngitis, pharyngitis, respiratory disorder, rhinitis, upper respiratory tract infection, angina tonsillaris, pulmonary disease^[Ref]

Dermatologic

• Common (1% to 10%): Acquired lipodystrophy, rash, pruritus, dry skin, eczema, alopecia, lipoatrophy
• Uncommon (0.1% to 1%): Stevens-Johnson syndrome, bullous dermatitis
• Frequency not reported: Acne, drug eruption, erythema, severe cutaneous reaction associated with increased liver function tests, increased sweating, urticaria, dermatitis, bullous dermatitis skin eruption (including with polyarthritis), folliculitis, furunculosis, hair changes, hot flushes, maculopapular rash, photosensitivity reaction, seborrheic dermatitis, skin disorder, skin nodule, skin pigment changes, skin ulceration, verruca, xeroderma, exanthema, nail disorders, night sweats, psoriasis
• Postmarketing reports: Lipodystrophy (including loss of peripheral and facial subcutaneous fat, increased intraabdominal and visceral fat, breast hypertrophy, dorsocervical fat accumulation [buffalo hump])^[Ref]

Nervous system

• Common (1% to 10%): Headache, paresthesia, peripheral neuropathy, dizziness, dysgeusia/taste alteration
• Uncommon (0.1% to 1%): Somnolence, convulsions
• Frequency not reported: Abnormal coordination, hypoesthesia, intracranial hemorrhage (sometimes leading to death), tremor, loss of consciousness, syncope, tinnitus, dysarthria, dysesthesia, ataxia, extremity numbness, face numbness, facial pain, hyperesthesia, hyperreflexia, hyporeflexia, lethargy, lightheadedness, paresis, poliomyelitis, progressive multifocal leukoencephalopathy, seizures, spasms, decreased hearing, stroke, myelopolyradiculoneuritis, prickly sensation^[Ref]

Psychiatric

• Common (1% to 10%): Decreased libido, sleep disorder
• Frequency not reported: Anxiety/anxiety attack, confusion/confusional state, depression, insomnia, libido disorder, psychotic disorder/psychosis, suicide attempt, agitation, amnesia, euphoria, excessive dreaming, hallucination, irritability, overdose effect, psychic disorders, reduced intellectual ability, speech disorder^[Ref]

Musculoskeletal

• Common (1% to 10%): Back pain, muscle spasms
• Frequency not reported: Arthralgia, myalgia, polyarthritis, elevated blood creatine phosphokinase, arthritis, muscle cramps, musculoskeletal pain, musculoskeletal disorders, stiffness, tissue changes, trauma, leg cramps

Combination antiretroviral therapy:

• Frequency not reported: Osteonecrosis

Protease inhibitor therapy:

• Rare (less than 0.1%): Rhabdomyolysis
• Frequency not reported: Increased creatine phosphokinase, myalgia, myositis^[Ref]

Hypersensitivity

• Common (1% to 10%): Hypersensitivity
• Frequency not reported: Allergic reaction, drug fever^[Ref]

Renal

• Common (1% to 10%): Increased blood creatinine
• Uncommon (0.1% to 1%): Renal impairment
• Frequency not reported: Nephrolithiasis, acute renal insufficiency^[Ref]

Ocular

• Uncommon (0.1% to 1%): Visual impairment
• Frequency not reported: Blepharitis, dry eye syndrome, eye irritation, visual disturbance, xerophthalmia, chalazion, cytomegalovirus retinitis^[Ref]

Immunologic

• Frequency not reported: Immune reconstitution/reactivation syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)^[Ref]

Genitourinary

• Frequency not reported: Enlarged prostate, pelvic pain, vaginal discharge, micturition disorder, urinary tract infection, epididymitis, impotence, menstrual disorder, menstrual irregularity, nocturia, penis disorder, renal calculus, renal colic, urinary tract bleeding^[Ref]

Oncologic

• Frequency not reported: Acute myeloid leukemia, papillomatosis, skin papilloma, tumor^[Ref]

Endocrine

• Frequency not reported: Hyperprolactinemia, increased thyroid stimulating hormone^[Ref]

Further information

Invirase side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer